HRP20040077A2 - Crystalline forms vi and vii of atorvastatin-calcium - Google Patents

Crystalline forms vi and vii of atorvastatin-calcium

Info

Publication number
HRP20040077A2
HRP20040077A2 HR20040077A HRP20040077A HRP20040077A2 HR P20040077 A2 HRP20040077 A2 HR P20040077A2 HR 20040077 A HR20040077 A HR 20040077A HR P20040077 A HRP20040077 A HR P20040077A HR P20040077 A2 HRP20040077 A2 HR P20040077A2
Authority
HR
Croatia
Prior art keywords
atorvastatin
vii
calcium
crystalline forms
crystalline
Prior art date
Application number
HR20040077A
Other languages
English (en)
Inventor
M Satyanarayana Reddy
Chakilam Nagaraju
Gudipati Srinivasulu
Katakam Sinivas
Sagyam Rajeswar Reddy
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of HRP20040077A2 publication Critical patent/HRP20040077A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20040077A 2001-07-30 2004-01-26 Crystalline forms vi and vii of atorvastatin-calcium HRP20040077A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
PCT/US2002/000431 WO2003011826A1 (fr) 2001-07-30 2002-01-07 Formes cristallines vi et vii de calcium d'atorvastatine

Publications (1)

Publication Number Publication Date
HRP20040077A2 true HRP20040077A2 (en) 2004-06-30

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040077A HRP20040077A2 (en) 2001-07-30 2004-01-26 Crystalline forms vi and vii of atorvastatin-calcium

Country Status (19)

Country Link
EP (2) EP2292600A1 (fr)
JP (1) JP2005500351A (fr)
KR (1) KR20040019043A (fr)
CN (1) CN100471836C (fr)
AU (1) AU2002255479B2 (fr)
BG (1) BG108518A (fr)
BR (1) BR0211488A (fr)
CA (1) CA2454500C (fr)
CZ (1) CZ2004126A3 (fr)
EE (1) EE200400048A (fr)
HR (1) HRP20040077A2 (fr)
IL (2) IL159626A0 (fr)
MX (1) MXPA04000889A (fr)
NO (1) NO20040390L (fr)
NZ (1) NZ530785A (fr)
PL (1) PL368647A1 (fr)
RU (1) RU2304139C2 (fr)
WO (1) WO2003011826A1 (fr)
ZA (1) ZA200400573B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
EP1480950A4 (fr) * 2002-02-15 2005-05-18 Teva Pharma Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et procedes pour leur preparation, ainsi que procedes nouveaux pour la preparation des formes i,viii et ix d'hemi-calcium d'atorvastatine
CA2475123A1 (fr) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique
EP1572643A2 (fr) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Forme cristalline du sel hemi calcique de l'atorvastatine
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2627940A1 (fr) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Procede de production d'atorvastatine calcique sous forme amorphe
WO2005090301A1 (fr) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Forme cristalline d'hemi-calcium d'atorvastatine
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1771412A2 (fr) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl)-bet a, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept acide anoique sel de calcium (2:1)
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
SI0848705T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
ES2349364T3 (es) 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
PL362981A1 (en) * 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)

Also Published As

Publication number Publication date
ZA200400573B (en) 2005-05-11
JP2005500351A (ja) 2005-01-06
CA2454500A1 (fr) 2003-02-13
EP1414796A1 (fr) 2004-05-06
CZ2004126A3 (cs) 2004-12-15
CN1537098A (zh) 2004-10-13
PL368647A1 (en) 2005-04-04
BR0211488A (pt) 2004-08-17
CA2454500C (fr) 2009-11-10
NZ530785A (en) 2005-10-28
EE200400048A (et) 2004-04-15
AU2002255479B2 (en) 2008-09-11
IL159626A (en) 2013-04-30
EP2292600A1 (fr) 2011-03-09
CN100471836C (zh) 2009-03-25
RU2004103470A (ru) 2005-06-20
MXPA04000889A (es) 2004-06-03
BG108518A (en) 2004-08-31
WO2003011826A1 (fr) 2003-02-13
NO20040390L (no) 2004-01-29
RU2304139C2 (ru) 2007-08-10
IL159626A0 (en) 2004-06-01
KR20040019043A (ko) 2004-03-04

Similar Documents

Publication Publication Date Title
HRP20040077A2 (en) Crystalline forms vi and vii of atorvastatin-calcium
TW479494U (en) Structure of pillow
AU2002362061A8 (en) Preparation of orlistat and orlistat crystalline forms
HUP0402536A3 (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof
EP1430054A4 (fr) Purification et des formes cristallines de zaleplon
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
IL159266A0 (en) Crystalline forms of fexofenadine and processes for the preparation thereof
GB0115581D0 (en) Method of mass spectometry
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2002322445A1 (en) Crystals and structures of arnb aminotransferases
TW493498U (en) Structure improvement of screwdriver
IL161608A0 (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
AU2002357159A8 (en) Manufacture of trialkylaluminum compounds and alpha-alcohols
EP1414427A4 (fr) Compositions a base de kavalactone et leurs procedes d'utilisation
IL157243A0 (en) Preparation of n-methylparoxetine and related intermediate compounds
TW493722U (en) Improved structure of lampwick
EP1435953A4 (fr) Composes antivesicants et procedes de fabrication et d'utilisation associes
TW484490U (en) Structural improvement of multiple-functional wrench
HU0104370D0 (en) Honeyed schnaps of oerseg
SI1448564T1 (sl) Substituirane indolizinu podobne spojine in postopki uporabe
GB0127380D0 (en) Formation of small crystals
GB0111083D0 (en) Formation of small crystals
TW484488U (en) Improved structure of quick-withdrawn wrench
TW493490U (en) Improved structure of wrench
AU2002365245A8 (en) Crystal structure of yqej and uses thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn